Company Announcements - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project with a total order value of approximately 15 billion yuan, expected to start mass production in 2027 [1] - Shangluo Electronics plans to acquire 88.79% of Ligon Technology for 700 million yuan, focusing on authorized distribution of storage chips and various IC products [2][3] - Xinda Zheng intends to purchase at least 51% of Jiaxin Liheng Facility Management (Shanghai) Co., Ltd., with the stock currently suspended [1] - Dingtong Technology plans to invest up to 15 million USD to establish a wholly-owned subsidiary in Vietnam for R&D and production of optical module liquid cooling products [1][3] - Kexing Pharmaceutical's shareholders are inquiring about transferring shares at an initial price of 30.88 yuan per share, which is a 28% discount compared to the closing price [4] - Zhongtai Automobile has been ordered to pay 29.5 million yuan plus overdue interest due to a court ruling, which may significantly impact its current or future performance [5] - Shoukai Co., Ltd. has seen a significant increase in shareholder numbers and some institutional shareholders have reduced their holdings [5] Investment and Contracts - Laofengxiang plans to jointly invest in establishing Laofengxiang Precision Materials Company to build a modern refining and testing laboratory [8] - Longci Technology intends to invest 210 million yuan in the second phase of its Vietnam project to localize the supply of permanent magnet ferrite raw materials [9] - Sileck has signed a 230 million yuan investment cooperation agreement for a new energy precision structural components project [10] Shareholding Changes - Jingchen Co. plans to acquire 316 million yuan for 100% of Chip Micro Semiconductor [6] - Beijing Junzheng has seen a reduction of 4.8254 million shares by its shareholder Beijing Yitang Shengxin [5] - Green Harmony's actual controllers have completed a reduction of 2.99% of their shares [7] - Hangke Technology's actual controller plans to transfer 3% of the total share capital [7] Stock Price Movements - Nanfeng Co. has reported that its 3D printing service project has not yet materialized, which may affect its current year's revenue and profit [3] Other Developments - Borui Pharmaceutical's BGM0504 tablets have been approved for clinical trials in overweight/obese adults, with no similar oral formulations approved globally [4] - Southwest Securities' subsidiary will lose its listing status on September 29 due to failure to meet resumption guidelines [20]

Suspension - New Dazheng is planning to issue shares and pay cash to acquire no less than 51% equity of Jiaxin Liheng Facility Management (Shanghai) Co., Ltd., and is raising matching funds, resulting in stock suspension [1] Mergers and Acquisitions - Jingchen Co., Ltd. intends to acquire 100% equity of Chipmike Semiconductor for a total consideration of 316 million yuan [2] - Shangluo Electronics plans to acquire 88.79% equity of Ligon Technology, a distributor of IC products, for 700 million yuan [3] Share Buybacks and Equity Transfers - Canrui Technology plans to repurchase shares for 20 million to 40 million yuan, with a maximum repurchase price of 52.46 yuan per share [4] - Kejie Intelligent is adjusting its maximum repurchase price from 15.77 yuan per share to 23.73 yuan per share [4] - Xindian Software's chairman proposed a share repurchase of 30 million to 50 million yuan [4] - Industrial Fulian is repurchasing and canceling 1.2855 million restricted stock options [5] - Kexing Pharmaceutical's shareholder inquiry transfer is preliminarily priced at 30.88 yuan per share, representing a 28% discount from today's closing price [6] - Hangke Technology's actual controller, Cao Ji, plans to transfer 3% of the total share capital through inquiry [7] External Investments and Daily Operations - Junsheng Electronics' subsidiary has recently secured a global automotive intelligence project worth approximately 15 billion yuan, with production planned to start in 2027 [8] - Sileck has signed an investment cooperation agreement for a 230 million yuan new energy precision structural components project [9] - Longmag Technology's wholly-owned subsidiary in Vietnam plans to invest approximately 210 million yuan to construct a second-phase project, adding 10,000 tons of permanent magnet ferrite wet-pressed magnetic tile capacity and supporting 25,000 tons of pre-burned material capacity [9] - Kangtai Biological's Sabin strain inactivated polio vaccine (Vero cells) has been approved for market launch [10] - Zhongding Co., Ltd. possesses core technology in humanoid robots and has signed strategic cooperation agreements with multiple enterprises [11] - Dingtong Technology plans to invest 15 million USD to establish a wholly-owned subsidiary in Vietnam for the research and production of optical module liquid cooling radiators [12] - Borui Pharmaceutical's BGM0504 tablets have been approved for clinical trials in overweight/obese adult patients, with no similar oral formulations approved globally [12] - Longmag Technology plans to invest 210 million yuan in the second phase of its Vietnam project to achieve localized supply of permanent magnet ferrite raw materials [13]

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]

受让方通过询价转让受让的股份，在受让后 6 个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 30.88 元/股。 （二）参与本次询价转让报价及申购的机构投资者家数为 21 家，涵盖了基 金管理公司、证券公司、合格境外机构投资者、私募基金管理人等专业机构投资 者。参与本次询价转让报价及申购的机构投资者合计有效认购股份数量为 10,190,000 股，对应的有效认购倍数为 1.01 倍。 证券代码：688136 证券简称：科兴制药 公告编号：2025-076 科兴生物制药股份有限公司 股东询价转让定价情况提示性公告 股东深圳科益医药控股有限公司（以下简称"出让方"）保证向科兴生物制 药股份有限公司（以下简称"公司"）提供的信息内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 9 月 15 日询价申购情况，初步确定的本次询价转让价格为 30.88 元/股。 1 经营。 特此公告。 科兴生物制药股份有限公司董事会 2025 ...

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

转自：智通财经 【科兴制药：股东询价转让初步定价为30.88元/股 较今日收盘价折价28%】智通财经9月15日电，科兴 制药(688136.SH)公告称，根据2025年9月15日询价申购情况，初步确定的本次询价转让价格为30.88元/ 股。参与报价及申购的机构投资者家数为21家，合计有效认购股份数量为1019万股，对应的有效认购倍 数为1.01倍。本次询价转让拟转让股份已获全额认购，初步确定受让方为21家机构投资者，拟受让股份 总数为1006.28万股。小财注：科兴制药今日收盘价42.81元/股，询价转让价较收盘价折价28%。 ...

（文章来源：每日经济新闻） 每经AI快讯，9月15日，科兴制药(688136.SH)公告称，根据2025年9月15日询价申购情况，初步确定的 本次询价转让价格为30.88元/股。参与报价及申购的机构投资者家数为21家，合计有效认购股份数量为 10,190,000股，对应的有效认购倍数为1.01倍。本次询价转让拟转让股份已获全额认购，初步确定受让 方为21家机构投资者，拟受让股份总数为10,062,800股。 ...

南方财经9月15日电，科兴制药(688136.SH)于9月15日公告，公司控股股东深圳科益医药控股有限公司 （简称"科益医药"）发布询价转让计划，拟以非公开方式向符合资格的机构投资者转让公司5%股份， 即1006.28万股。转让原因为自身经营发展需要，由中金公司担任组织券商，转让底价不低于认购邀请 书发送日前20个交易日公司股票均价的70%。此前披露的转让结果显示（2025年8月6日公告），科益医 药已于8月通过询价转让完成603.77万股交易，占总股本的3%，成交价为36.70元/股。工银瑞信、财通 基金、J.P.摩根等13家机构投资者成功获配，所获股份均设6个月限售期。 ...

中国经济网北京9月15日讯 科兴制药(688136.SH)昨日晚间披露股东询价转让计划书，本次拟参与科兴制药首发前股东询价转让 （以下简称"本次询价转让"）的股东为深圳科益医药控股有限公司（以下简称"科益医药"），出让方拟转让股份的总数为10,062,800 股，占公司总股本的比例为5.00%。 科兴制药首次公开发行股票的发行费用（含税）总额为1.15亿元，其中，保荐及承销费用9385.58万元。 另外，科兴制药2025年8月23日披露了关于筹划公司在香港联合交易所有限公司上市的提示性公告。据科兴制药公告，公司正在 筹划发行境外上市股份（H股）并在香港联合交易所有限公司上市（以下简称"本次H股上市"）。公司正与相关中介机构就本次H股 上市的具体推进工作进行商讨，相关细节尚未确定。 | 拟转让股东 | 拟转让股份数量 | | 占所持股份比例 | 转让原因 | | --- | --- | --- | --- | --- | | 姓名 | (股) | 本比例 | (截至 2025年9月12日) | | | 科益医药 | 10,062,800 | 5.00% | 8.40% | 自身经营发展需要 | 本次询价转让为非 ...

Core Viewpoint - The announcement details a share transfer plan by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd. to transfer 10,062,800 shares of Kexing Pharmaceutical, representing 5.00% of the total share capital, through a non-public inquiry transfer process [3][7]. Group 1: Share Transfer Details - The total number of shares to be transferred is 10,062,800, which accounts for 5.00% of the company's total share capital [3][7]. - The transfer is organized by China International Capital Corporation (CICC) and is not conducted through public trading methods [3][10]. - The receiving party must be an institutional investor with appropriate pricing capabilities and risk tolerance [3][10]. Group 2: Seller Information - The seller, Shenzhen Keyi Pharmaceutical, is the controlling shareholder of Kexing Pharmaceutical, with a shareholding exceeding 5% [3][4]. - The seller has confirmed that the shares are free from any transfer restrictions and have been released from lock-up [4][5]. Group 3: Pricing Mechanism - The minimum transfer price will not be lower than 70% of the average trading price of the company's shares over the 20 trading days prior to the issuance of the subscription invitation [8]. - The pricing determination will follow a priority system based on subscription price, quantity, and time of submission [9]. Group 4: Company Status - Kexing Pharmaceutical does not have any undisclosed operational risks or potential changes in control related to this share transfer [11]. - There are no other significant undisclosed matters concerning the company [11].